Search Result

Isoforms Recommended:	PI3Kδ

Results for "

p110δ

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Apoptosis (4) Autophagy (5) DNA-PK (2) mTOR (5) PI3K (24)
By Research Areas:	Cancer (22) Cardiovascular Disease (1) Inflammation/Immunology (2) Metabolic Disease (1)

Inhibitors & Agonists

Isotope-Labeled Compounds

Antibodies

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-114428

P110δ-IN-1

PI3K Cancer

P110δ-IN-1 is a potent and selective inhibitor of P110δ extracted from patent WO 2014055647 A1, with an IC₅₀ of 8.4 nM .

P110δ-IN-1	PI3K	Cancer
P110δ-IN-1 is a potent and selective inhibitor of *P110δ* extracted from patent WO 2014055647 A1, with an IC₅₀ of 8.4 nM .

HY-13026S

Idelalisib-d5 CAL-101 d₅; GS-1101 d₅	PI3K Autophagy	Cancer
Idelalisib-d₅ is a deuterium labeled Idelalisib. Idelalisib is a highly selective and orally bioavailable p110δ inhibitor[1].

HY-111184

PIK-108

PI3K Cancer

PIK-108 is a non-ATP competitive, allosteric p110β/p110δ selective inhibitor .

PIK-108	PI3K	Cancer
PIK-108 is a non-ATP competitive, allosteric *p110β/p110δ* selective inhibitor .

HY-13026

Idelalisib 35+ Cited Publications CAL-101; GS-1101	PI3K Autophagy	Cancer
Idelalisib (CAL-101; GS-1101) is a highly selective and orally bioavailable *p110δ* inhibitor with an IC₅₀ of 2.5 nM, showing 40- to 300-fold selectivity for p110δ over other PI3K class I enzymes.

HY-109198

Zandelisib ME-401; PWT-143	PI3K	Cancer
Zandelisib (ME-401) is a phosphatidylinositol 3-kinase (PI3K) inhibitor extracted from patent WO2019183226 A1, Compound Example 1. Zandelisib selectively inhibits *p110δ* with an IC₅₀ of 3.5 nM. Zandelisib functions as an antineoplastic .

HY-10303

PIK-294

1 Publications Verification

PI3K Cancer

PIK-294 is a potent p110δ-selective inhibitor with an IC₅₀ of 10 nM.
HY-111510

IPI-3063

PI3K Inflammation/Immunology

IPI-3063 is a potent and selective PI3K p110δ inhibitor with an IC₅₀ of 2.5 ± 1.2 nM.

PIK-294 1 Publications Verification	PI3K	Cancer
PIK-294 is a potent *p110δ*-selective inhibitor with an IC₅₀ of 10 nM.

IPI-3063	PI3K	Inflammation/Immunology
IPI-3063 is a potent and selective PI3K p110δ inhibitor with an IC₅₀ of 2.5 ± 1.2 nM.

HY-17044

Duvelisib 5+ Cited Publications IPI-145; INK1197	PI3K	Cancer
Duvelisib (IPI-145) is a selectivite p100δ inhibitor with IC₅₀ of 2.5 nM, 27.4 nM, 85 nM and 1602 nM for p110δ, P110γ, p110β and p110α, respectively .

HY-70063

Buparlisib 55+ Cited Publications BKM120; NVP-BKM120	PI3K Apoptosis	Cancer
Buparlisib (BKM120; NVP-BKM120) is a pan-class I PI3K inhibitor, with IC₅₀s of 52, 166, 116 and 262 nM for *p110α, p110β, p110δ* and *p110γ*, respectively.

HY-13504

PIK-293 1 Publications Verification	PI3K	Metabolic Disease Cancer
PIK-293, an analog of IC87114, is a PI3K inhibitor, with IC₅₀ values of 0.24 μM, 10 μM, 25 μM and 100 μM for p110δ, p110β, p110γ and p110α, respectively .

HY-160418

PI3K-IN-51

PI3K Cancer

PI3K-IN-51 is a PI3K inhibitor with IC₅₀ values <500 nM for p120γ and p110δ/p85α (WO2016204429A1; Example 10) .

PI3K-IN-51	PI3K	Cancer
PI3K-IN-51 is a PI3K inhibitor with IC₅₀ values <500 nM for p120γ and p110δ/p85α (WO2016204429A1; Example 10) .

HY-15245

GSK2636771 5+ Cited Publications	PI3K	Cancer
GSK2636771 is a potent, selective and orally bioavailable inhibitor of PI3Kβ with a K_i of 0.89 nM and an IC₅₀ of 5.2 nM, showing 900-fold selectivity over p110α and p110γ, and 10-fold selectivity over p110δ isoforms.

HY-N6775

Sonolisib 1 Publications Verification PX-866	PI3K	Cancer
Sonolisib (PX-866), an improved Wortmannin analogue, is an oral, irreversible, and pan-isoform inhibitor of PI3K (IC₅₀=0.1 nM (p110α), 1.0 nM (p120γ), 2.9 nM (p110δ)). Antitumor activity .

HY-12235

PI-3065 3 Publications Verification	PI3K	Inflammation/Immunology Cancer
PI-3065 is a potent inhibitor of PI3K p110δ, with IC₅₀ and K_i values of 5 nM and 1.5 nM, and exhibits less potent activity against p110α, p110β, p110γ with IC₅₀s of 910, 600, >10000 nM.

HY-15180

Buparlisib Hydrochloride 55+ Cited Publications BKM120 Hydrochloride; NVP-BKM120 Hydrochloride	PI3K Apoptosis	Cancer
Buparlisib Hydrochloride (BKM120 Hydrochloride) is a pan-class I PI3K inhibitor, with IC₅₀ of 52 nM/166 nM/116 nM/262 nM for *p110α/p110β/p110δ/p110γ*, respectively.

HY-15244A

Alpelisib hydrochloride BYL-719 hydrochloride	PI3K	Cancer
Alpelisib hydrochloride (BYL-719 hydrochloride) is a potent, orally active, and selective PI3Kα inhibitor with IC₅₀s of 5 nM, 250 nM, 290 nM and 1200 nM for *p110α, p110γ, p110δ, and p110β*, respectively. Alpelisib hydrochloride (BYL-719 hydrochloride) shows antineoplastic activity .

HY-10108A

LY294002 hydrochloride
LY294002 hydrochloride is a potent and broad-spectrum PI3K inhibitor, with IC₅₀ values of 0.5, 0.57, and 0.97 μM for *P110α, P110δ* and *P110β, respectively. LY294002 hydrochloride also inhibits CK2* with an IC₅₀ of 98 nM. LY294002 hydrochloride can be used for pancreatic cancer research .

HY-156371

MIPS-21335	PI3K	Cardiovascular Disease
MIPS-21335 is an PI3KC2α inhibitor (IC₅₀: 7 nM). MIPS-21335 also inhibits PI3KC2β, p110α, p110β and p110δ (IC₅₀: 0.043, 0.140, 0.386, 0.742 μM). MIPS-21335 has antithrombotic effect .

HY-10115

PI-103 15+ Cited Publications	PI3K mTOR DNA-PK Autophagy Apoptosis	Cancer
PI-103 is a potent PI3K and mTOR inhibitor with IC₅₀s of 8 nM, 88 nM, 48 nM, 150 nM, 20 nM, and 83 nM for *p110α, p110β, p110δ, p110γ, mTORC1, and mTORC2. PI-103 also inhibits DNA-PK* with an IC50 of 2 nM. PI-103 induces autophagy .

HY-10115A

PI-103 Hydrochloride 15+ Cited Publications	PI3K mTOR DNA-PK Autophagy Apoptosis	Cancer
PI-103 Hydrochloride is a dual PI3K and mTOR inhibitor with IC₅₀s of 8 nM, 88 nM, 48 nM, 150 nM, 20 nM, and 83 nM for *p110α, p110β, p110δ, p110γ, mTORC1, and mTORC2. PI-103 Hydrochloride also inhibits DNA-PK* with an IC50 of 2 nM. PI-103 Hydrochloride induces autophagy .

HY-50673

Dactolisib 45+ Cited Publications BEZ235; NVP-BEZ235	PI3K mTOR Autophagy	Cancer
Dactolisib (BEZ235) is an orally active and dual pan-class I PI3K and mTOR kinase inhibitor with IC₅₀s of 4 nM/5 nM/7 nM/75 nM, and 20.7 nM for *p110α/p110γ/p110δ/p110β* and mTOR, respectively. Dactolisib (BEZ235) inhibits both mTORC1 and mTORC2.

HY-108418

PI3Kδ-IN-15	PI3K	Cancer
PI3Kδ-IN-15 (compound 6b) is a selective PI3Kδ inhibitor with an IC₅₀ of 0.5 nM for p110δ. PI3Kδ-IN-15 inhibits PI3Kδ with >30-fold higher potency than PI3Kγ, PI3Kβ, and PI3Kα .

HY-15244

Alpelisib 75+ Cited Publications BYL-719	PI3K	Cancer
Alpelisib (BYL-719) is a potent, selective, and orally active PI3Kα inhibitor. Alpelisib (BYL-719) shows efficacy in targeting PIK3CA-mutated cancer. Alpelisib (BYL-719) also inhibits p110α/p110γ/p110δ/p110β with IC₅₀s of 5/250/290/1200 nM, respectively. Antineoplastic activity .

HY-15900

Voxtalisib 4 Publications Verification XL765; SAR245409	PI3K mTOR	Cancer
Voxtalisib (XL765) is a potent PI3K inhibitor, which has a similar activity toward class I PI3K (IC₅₀s=39, 113, 9 and 43 nM for *p110α, p110β, p110γ* and *p110δ, respectively), also inhibits DNA-PK (IC₅₀=150 nM) and mTOR (IC₅₀=157 nM). Voxtalisib (XL765) inhibits mTORC1* and mTORC2 with IC₅₀s of 160 and 910 nM, respectively.

HY-10116

PI-540	PI3K mTOR	Cancer
PI-540 is a bicyclic thienopyrimidine derivative and an orally active PI3K inhibitor. PI-540 has anti-cancer cell proliferation properties and high tissue distribution. PI-540 can inhibit different isoforms of PI3K, with IC₅₀s of 10 nM (P110α), 3510 nM (P110β), 410 nM (P110δ), and 33110 nM (P110γ). PI-540 also inhibits mTOR (IC₅₀: 61 nM) and DNA-PK (IC₅₀: 525 nM) .

Idelalisib-d5
Idelalisib-d₅ is a deuterium labeled Idelalisib. Idelalisib is a highly selective and orally bioavailable p110δ inhibitor[1].

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Name
Email *

	Sorry, but the email address you supplied was invalid.